Les 10 concurrents kodiak.com les plus visités

kymeratx.com

Kymera is a clinical stage company pioneering targeted protein degradation to deliver revolutionary treatments for patients around the world.

relaytx.com

Relay Therapeutics puts protein motion at the heart of drug discovery to dramatically expand therapeutic possibilities.

eledon.com

TEGOPRUBART’s Multiple Mechanisms of Action Could Help Effectively Manage Immune Response Tegoprubart targets the CD40 ligand (also known as CD40L and CD154). Blocking CD40L has been shown to inhibit multiple costimulatory receptors including CD40 and CD11, key components of how immune cells communicate with one another. Blocking CD40L also increases polarization of lymphocytes into Tregs, […]

cognitotx.com

Cognito is developing disease-modifying treatments to revive the health and well-being of patients living with Alzheimer’s.

vial.com

Stay in the know about everything Vial with our latest press releases. Keep up-to-date on our innovations, milestones, and industry impact.

monterosatx.com

Pioneering Therapies for Cancer and Beyond – Our drug discovery platform is tailored to promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, undruggable proteins, in essence leading to pharmacological protein knockout with high efficiency and accuracy.

codexis.com

Codexis: RNA manufacturing and custom enzyme engineering for pharmaceuticals and siRNA therapeutics.

praxismedicines.com

DAREFORMORE® We dare for more in every aspect of what we do – advancing our portfolio of precision therapies for central nervous system disorders – to make the impossible possible. Learn About Our Methodology The field of neurology has been primed for a revolution in how new therapies are discovered. We have taken the

bicycletherapeutics.com

RECRUITMENT CANDIDATE PRIVACY NOTICE

formation.bio

We are excited about AI’s potential to meaningfully address the drug development bottleneck. We have begun incorporating LLMs and AI models in everything we do, and our plans for AI innovation and investment span short, medium, and long term horizons.